Clinical trials
Bevacizumab clinical trials
Below are recruiting bevacizumab clinical trials, each written for real people, not researchers. We’re tracking 422 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT04250064RecruitingPhase 2
Low-dose bevacizumab with standard radiation for DIPG
This Phase 2 study tests whether adding low-dose bevacizumab (a medicine that affects blood vessel growth) to standard radiation can help children newly diagnosed with DIPG. It’s meant for certain children with a specific type of brain tumor that has not spread.
Mumbai, MaharashtraAges 3–18 - NCT07198074RecruitingPhase 3
Testing Avastin added to chemo plus Keytruda for certain endometrial cancer
This study tests adding Avastin (bevacizumab) to the standard combination of chemotherapy (carboplatin and paclitaxel) plus immunotherapy (Keytruda) for advanced or recurrent endometrial cancer with a specific genetic makeup (pMMR and TP53 mutation). The goal is to see if adding Avastin helps shrink tumors or slow their growth.
Birmingham, AlabamaAges 18 years+ - NCT07179900RecruitingPhase 2
Radiation plus two drugs for liver cancer that can't be removed
This trial tests a combination of radiation therapy with two drugs (QL1706 and bevacizumab) for people with liver cancer that hasn't spread to other parts of the body but can't be surgically removed. The goal is to see if this approach can shrink or control the tumor.
Shijiazhuang, HebeiAges 18 years+ - NCT07150208RecruitingPhase 2
T-DXd with or without Avastin for HER2-low breast cancer that spread to the brain
This trial tests a combination of two targeted drugs (T-DXd and bevacizumab) for people with HER2-low breast cancer that has spread to the brain. It aims to see if adding bevacizumab helps the main drug work better against brain metastases.
ShanghaiAges 18–70 - NCT06401824RecruitingPhase 2
Combination drug therapy for lung cancer with brain spread
This trial tests a combination of two drugs, sacituzumab govitecan and bevacizumab, for people with a specific type of lung cancer (non-squamous) that has spread to the brain. It aims to see if this treatment can shrink brain tumors and improve outcomes.
AmsterdamAges 18 years+ - NCT07106034RecruitingPhase 2
Testing a new combo therapy for advanced colorectal cancer
This trial tests a combination of two drugs (ONGERICIMAB and TORIPALIMAB) for people with a specific type of colorectal cancer that did not respond to first treatment. It aims to see if this new approach can help shrink or control the cancer.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT06459687RecruitingPhase 3
Socazolimab for first-line treatment of advanced cervical cancer
This phase 3 trial tests a new immunotherapy drug called socazolimab combined with chemotherapy as a first treatment for cervical cancer that has come back, spread, or cannot be removed with surgery or radiation. The goal is to see if it helps shrink tumors and improves survival.
Hefei, AnhuiAges 18–75 - NCT07090525RecruitingPhase 2
Bevacizumab plus cisplatin vs. cisplatin alone for fluid buildup from cancer
This trial tests whether adding bevacizumab (a drug that blocks blood vessel growth) to cisplatin (a standard chemotherapy) is better than cisplatin alone for controlling fluid buildup caused by adenocarcinoma. If you have not had prior treatment for this fluid, you may qualify.
Qingdao, ShandongAges Any age - NCT06976671RecruitingPhase 2
Testing bevacizumab injection for frozen shoulder
This trial tests an injection of bevacizumab into the shoulder joint for people with frozen shoulder (adhesive capsulitis). The goal is to see if it can reduce pain and stiffness.
North Ryde, New South WalesAges 18 years+ - NCT07065435RecruitingPhase 2
RC48 with Avastin or Pyrotinib for HER2+ breast cancer after T-DXd
This trial tests a new combination of drugs (RC48 plus either Avastin or Pyrotinib) for people with HER2-positive breast cancer that has spread and has stopped responding to the drug T-DXd. The goal is to see if these combinations can help shrink tumors and control the cancer longer.
Nanjing, JiangsuAges 18–75 - NCT07058428RecruitingPhase 3
FSRT with Avastin for multiple brain tumors from lung cancer
This trial tests giving focused radiation (FSRT) along with Avastin (bevacizumab) to people with multiple brain metastases from lung adenocarcinoma. It aims to see if combining these treatments is safe and effective for tumors that are too large or numerous for standard one-time radiation.
Guangzhou, GuangdongAges 18 years+ - NCT07059494RecruitingPhase 4
Combination therapy for liver cancer before transplant
This trial tests a combination of two drugs (atezolizumab and bevacizumab) plus a targeted radiation treatment (Y-90 radioembolization) for people with liver cancer who are waiting for a liver transplant. The goal is to see if this treatment can help control the cancer and improve transplant outcomes.
New York, New YorkAges 18 years+ - NCT07044908RecruitingPhase 1/Phase 2
New drug combo for advanced colorectal cancer
This trial tests a new drug called TQB2922 combined with TAS-102, with or without bevacizumab, for people whose advanced colorectal cancer has a normal RAS and BRAF gene and has not responded to standard chemotherapy. The goal is to see if this combination can slow or stop cancer growth.
Hefei, AnhuiAges 18–75 - NCT07054567RecruitingPhase 2
Study of BL-B01D1 plus Keytruda for advanced cervical or endometrial cancer
This trial tests a new drug combination for people with cervical or endometrial cancer that has come back or spread. The study aims to see if adding BL-B01D1 to Keytruda (with or without Avastin) can help shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–75 - NCT07047560RecruitingPhase 2
A new chemo combo for advanced colorectal cancer
This trial tests a different way of giving a chemotherapy drug called irinotecan, along with two other drugs (5-FU and bevacizumab), for people whose cancer got worse after first-line treatment. It aims to see if this combination can help control the cancer.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07042802RecruitingPhase 1/Phase 2
LBL-024 with chemotherapy for recurrent ovarian cancer
This trial is testing a new drug, LBL-024, combined with chemotherapy (with or without a targeted therapy called bevacizumab) for ovarian cancer that has stopped responding to standard platinum-based treatment. The goal is to see if this combination can effectively shrink tumors and slow the disease's progression.
Beijing, Beijing MunicipalityAges 18 years+ - NCT06992648RecruitingPhase 3
Two drug combos for advanced colorectal cancer
This trial tests a two-drug combination (trifluridine/tipiracil plus regorafenib) against a standard pair (trifluridine/tipiracil plus bevacizumab) for people with advanced colorectal cancer that has stopped responding to prior treatments. It aims to find which combination works better.
Hangzhou, ZhejiangAges 18 years+ - NCT07018947RecruitingPhase 2
Atezolizumab and bevacizumab before and after surgery for liver cancer
This trial tests whether adding two drugs (atezolizumab and bevacizumab) before and after surgery can lower the chance of liver cancer coming back in people with high-risk HCC. You must be eligible for surgical removal of your tumor.
Badalona, BarcelonaAges 18 years+ - NCT07012798RecruitingPhase 2
Sequential therapy for advanced liver cancer that may become removable
This trial tests a sequence of chemotherapy (FOLFOX), immunotherapy (durvalumab), targeted therapy (bevacizumab), and focused radiation to shrink liver tumors that are not removable now, with the goal of making them operable later.
Tianjin, Tianjin MunicipalityAges 18 years+ - NCT07012954RecruitingPhase 1/Phase 2
ctDNA-guided treatment for RAS/BRAF wild-type colorectal cancer
This trial tests a combination of two drugs—cetuximab or bevacizumab plus a chemotherapy pill (trifluridine/tipiracil)—for people with metastatic colorectal cancer that has no RAS or BRAF mutations. It's for patients whose cancer grew after first responding to cetuximab, and who have had other treatments since then.
Guangzhou, GuangdongAges 18–75 - NCT07005570RecruitingPhase 2
Short radiation and chemo with or without immunotherapy for rectal cancer
This trial tests if adding an immunotherapy drug (PD-1 inhibitor) and a targeted therapy (bevacizumab) to short-course radiation followed by chemo can improve outcomes for patients with locally advanced rectal cancer that is pMMR/MSS. The goal is to shrink the tumor before surgery and possibly avoid the need for more extensive treatment.
Guangzhou, GuangdongAges 18–75 - NCT06997497RecruitingPhase 3
Study of Calderasib with other drugs for colorectal cancer
This trial tests a new drug called Calderasib combined with targeted therapy or chemotherapy for people with advanced colorectal cancer that has a specific genetic change (KRAS G12C mutation). It may be an option for those who have not had prior treatment for advanced disease.
Phoenix, ArizonaAges 18 years+ - NCT07002346RecruitingPhase 3
Immunotherapy and bevacizumab for advanced ovarian clear cell cancer
This trial tests a combination of an immunotherapy drug (QL1706) and a targeted therapy (bevacizumab) for women with newly diagnosed advanced ovarian clear cell carcinoma. The goal is to see if this combination works better than standard treatment after surgery.
Wuhan, HubeiAges 18–75 - NCT06986785RecruitingPhase 2
Study of new drug combinations for advanced liver cancer
This trial tests a new drug called BL-B01D1, alone or together with other drugs, in people with advanced liver cancer that has not improved with other treatments. The goal is to see if these combinations can help shrink tumors or slow the cancer's growth.
Shanghai, Shanghai MunicipalityAges 18–75
Hear when a new Bevacizumab trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for bevacizumab?
- Yes. Clin2 currently lists 422 recruiting bevacizumab studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a bevacizumab trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a bevacizumab trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.